NVCR - NovoCure Limited Ordinary Shares -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
NovoCure Limited Ordinary Shares
NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.
IPO Date: September 28, 2015
Sector: Healthcare
Industry: Medical Instruments and Supplies
Market Cap: $1.66B
Activated in VL: True
Average Daily Range
Avg Daily Range: $1.39 | 3.03%
Avg Daily Range (30 D): $0.35 | 2.10%
Avg Daily Range (90 D): $0.55 | 3.29%
Institutional Daily Volume
Avg Daily Volume: .84M
Avg Daily Volume (30 D): .93M
Avg Daily Volume (90 D): 1.16M
Trade Size
Avg Trade Size (Sh.): 71
Avg Trade Size (Sh.) (30 D): 69
Avg Trade Size (Sh.) (90 D): 67
Institutional Trades
Total Institutional Trades: 6,396
Avg Institutional Trade: $3.15M
Avg Institutional Trade (30 D): $3.36M
Avg Institutional Trade (90 D): $3.71M
Avg Institutional Trade Volume: .07M
Avg Institutional Trades (Per Day): 2
Market Closing Trades
Avg Closing Trade: $5.23M
Avg Closing Trade (30 D): $3.74M
Avg Closing Trade (90 D): $4.13M
Avg Closing Volume: 121.09K
 
News
Sep 7, 2026 @ 3:12 PM
Novocure Reports Patient Data Exposure in Cybersec...
Source: Na
Jun 4, 2026 @ 4:39 PM
Stock Market Today, June 4: Broadcom Drags on Nasd...
Source: Emma Newbery
May 27, 2026 @ 5:00 PM
Glioblastoma Multiforme Market Poised for Signific...
Source: Delveinsight
Feb 17, 2026 @ 4:17 PM
New Treatment Modalities Are Reaching Cancers That...
Source: Prnewswire
Feb 13, 2026 @ 12:34 PM
Soleus Adds a Significant Number of Celcuity Share...
Source: Lawrence Rothman, Cfa
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-1.3 $-.13 $-.62
Diluted EPS $-1.3 $-.13 $-.62
Revenue $699.19M $183.58M $174.06M
Gross Profit $532.27M $142.48M $135.13M
Net Income / Loss $-148.57M $-15.66M $-71.14M
Operating Income / Loss $-154.4M $-10.56M $-67.42M
Cost of Revenue $166.92M $41.11M $38.93M
Net Cash Flow $-48.52M $6.29M $-6.07M
PE Ratio